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Abstract
Objective To analyse the single-nucleotide polymorphisms
(SNPs): ABCB11236C>T, ABCB12677G>T/A, ABCB13435C>T
and haplotypes in the ABCB1/MDR1 gene, which could
contribute to genetic risk of colorectal cancer (CRC).
Disease association between the ABCB1/MDR1 genotype,
allele, haplotype frequencies and histological features, such
as TNM classification, localization of primary carcinoma,
grade of malignancy, histological type of tumour, lymphoid
infiltration and vessel invasion were estimated. In this
study, the potential role of SNPs of the ABCB1/MDR1 gene
as a prognostic marker for CRC was analysed.
Materials and methods Tumour specimens of 95 patients
with CRC were studied. Using automated sequencing or
PCR-RFLP method, DNA for three common SNPs of
ABCB1/MDR1 was extracted and analysed. The results of
genotyping and haplotype analysis with histopathological
features, grading and clinical staging of neoplasms were
correlated.
Results A statistically significant higher frequency of T1236
allele in T1/T2 (89.7%), M0 groups (81.6%) and I/II
clinical staging (82.7%) in comparison with T3/T4 (68.2%),
M1 groups (47.4%) and III/IV clinical staging (65.1%) was
detected. Furthermore, multivariate analysis according to
Cox's proportional hazard model indicated that the T1236
allele is a good, independent prognostic factor and the
presence of this allele decreases the risk of death in
comparison with a group without this allele (HR=0.26;
p=0.0424). In addition, a statistically significant higher
frequency of C3435 allele and significant differences in the
C3435 allele distribution in N1/N2 group (91.7% and 62.5%,
respectively) than N0 group (71.2% and 44.9%, respectively)
was found. Each of the eight possible haplotypeswas noted in
M0 or I/II group and only seven in M1 or III/IV group.
Haplotype T1236-G2677-C3435 only in less advanced CRC
subjects (9.6% in I/II and 9.2% in M0 group) was detected.
In addition, significant differences in haplotype distributions
between M0 or I/II and M1 or III/IV group were found
(p=0.01 and p=0.05, respectively).
Conclusions These results suggest association between
T1236 allele and T1236-G2677-C3435 haplotype and less
advanced CRC, so these genetic markers may play a role
as potentially good prognostic factors. Differences in
haplotype distributions and degree of clinical staging may
suggest that some other potential SNPs, especially in
regulatory region of ABCB1/MDR1 gene, may influence
P-glycoprotein function and CRC progression.
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Introduction
Colorectal cancer (CRC) is one of the most frequent
neoplasms and is the main reason for the high mortality
ratio among different type cancer sufferers in industrial
countries [1]. Every year, in the European Union, there are
approximately 220,000 new cases of CRC diagnosed. The
number of deaths each year approaches 112,000 [2].
It is well documented that single nucleotide polymor-
phism (SNP) of some genes may be related to an increased
or decreased cancer risk. Among them, the ABCB1/MDR1
gene seems to play an important role in tumour progression
[3]. This gene belongs to ATP-binding cassette family and
encodes P-glycoprotein (P-gp), which is an efflux pump
protein of 170-kDa [3]. Overexpression of P-gp in tumour
cells leads to multidrug resistance against antineoplastic
agents [4–7]. P-gp is expressed in the apical membranes of
excretory tissues, such as liver, kidney and intestine. This
contributes to the elimination of toxic exogenous substan-
ces or metabolites and drugs into bile and urine or limits
drug absorption from the gastrointestinal tract [8, 9].
Authors have implicated P-gp in the system regulating cell
differentiation, proliferation [6], apoptosis [10] and immune
response [11].
The role of P-gp in carcinogenesis was described in animal
models of colon [12], breast [13] and liver [14] cancers.
Overexpression of P-gp was connected with apoptosis
inhibition and increasing possibility of neoplasm transforma-
tion in an mdr1a mouse model [12]. Moreover, high
expression of P-gp at the atypical surface of differentiated
tubular structures was identified in previously non-treated
CRC [15], and its high expression at the leading edge of CRC
has been associated with tumour progression [16]. A
transcription factor complex TCF4/ß-catenin responsive
element was identified recently in the ABCB1/MDR1
promoter region, pointing to a direct link between the
ABCB1/MDR1 gene and the Wnt signalling pathway, the
most important pathway that is altered in CRC [17]. In vitro
study indicated that the ABCB1/MDR1 gene expression is
activated in cells with the P53 gene mutation [18]. The
promoter of the human ABCB1/MDR1 gene was shown to be
a target for the P53 tumour suppressor gene products. Mutant
P53 specifically stimulated the ABCB1/MDR1 promoter and
wild-type P53 exerted specific repression [18]. Prevalence of
P53 mutations in CRC is around 50% [19].
Intensive studies into the implications of genetically
determined differences in P-gp function for drug disposi-
tion, therapeutic outcome, risk for development of certain
diseases and tumour progression are ongoing.
There exist multiple mutations in the ABCB1/MDR1 gene.
Analysis of all 28 exons of the ABCB1/MDR1 gene
demonstrated 48 single-nucleotide polymorphisms (SNPs),
including promoter and the intron–exon region [20]. The
most frequent SNPABCB12677G>T/A in exon 21 (RefSNP ID:
rs2032582), leads to amino acid exchange from Ala to Ser or
Thr. The silent mutation in exon 26 ABCB13435C>T (RefSNP
ID: rs1045642) is associated with altered protein function
[21]. The third common polymorphism of ABCB1/MDR1
gene is a silent mutation in exon 12 ABCB11236C>T (RefSNP
ID: rs1128503). The relationships between the SNPs of
ABCB1/MDR1 gene are not clear. Perhaps these three
polymorphisms are closely related to linkage disequilibrium
(LD), but an unknown genetic variant is located on the same
LD block or haplotype [20, 22]. Several studies show that
polymorphisms of ABCB1/MDR1 gene can influence sus-
ceptibility to cancer development. It was suggested that
ABCB13435C>T SNP is connected with susceptibility to renal
epithelial tumours [23] and acute lymphoblastic leukaemia
[24]. These SNPs were also reported in patients diagnosed
with CRC [25–29] and may contribute to the susceptibility
and progression of CRC [30].
The aim of this study is to determine the significance of
three SNPs of ABCB1/MDR1,n a m e l yABCB11236C>T,
ABCB12677G>T/A and ABCB13435C>T, in the progression of
CRC. We analysed the potential role of SNPs or haplotypes
of the ABCB1/MDR1 gene as a prognostic marker for CRC.
Materials and methods
Tissue samples from 95 colorectal carcinoma patients from
a region in Central Poland (48 women and 47 men, ratio
1:0.98, median age is 6) operated on in the Oncological
Center of Lodz, Poland were obtained. CRC was diagnosed
by histopathological examination using the established
clinical criteria (TNM classification by Jass with latest
revision Cancer Staging Manual by AJCC, 1997 [31]) at
the Department of Pathology, Medical University of Lodz,
Poland. Primary colorectal carcinoma and normal colorectal
mucosa (tissue taken from a site several centimetres away
from the tumour) in the study (estimated resection status of
all patients: R0) were used. Furthermore, 40 patients
(42.1%) qualified for combination adjuvant chemotherapy
5-fluorouracil and leucovorin (5-FU/LV), and 15 patients
(15.8%) were subjects to preoperative radiotherapy. Sam-
ples were frozen in liquid nitrogen immediately after
surgical resection and stored in the freezer at−80°C until
processed. All subjects were of Slavic origin. Detailed
information for the colorectal cancer group is summarised
in Table 1. All experiments were carried out with local
ethical committee approval (No KE/813/07) and patient's
informed consent.
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DNA was isolated according to “Genomic DNA Prep Plus”
protocol (A&A Biotechnology, Gdynia, Poland) from the
frozen tissue slides of colon cancer. The purity and
concentration of DNA samples were estimated spectropho-
tometrically. The samples were stored at−20°C until
analysis.
Polymerase chain reaction
Polymerase chain reaction (PCR) was conducted
according to the “AccuTaq™ LA DNA Polymerase
Kit” protocol (Sigma–Aldrich, Germany). The reaction
mixture for PCR amplification consisted of 50 ng of
DNA template, 0.5 μM of each primer, 10X AccuTaq
Buffer, 0.5 U of AccuTaq LA DNA Polymerase Mix,
0.2 mM each deoxyribonucleotide triphosphate (dNTP)
and water to a final volume of 20 μl. Negative control
was included in each experiment (sample without
DNA template). Primer design based on published
sequences for genotyping procedure of ABCB11236C>T,
ABCB12677G>T/A and ABCB13435C>T polymorphisms
using genomic DNA [21, 32, 33].
Restriction fragment length polymorphism
After checking PCR product in 2% agarose gel, amplified
DNA was cut for ABCB13435C>T mutation by restriction
enzyme MboI (Fermentas, Vilnius, Lithuania) over 16 h at
37°C according to Panczyk [32]. DNA fragments generated
after digestion were separated on 2% agarose gel and
visualised with ethidium bromide. The electrophoretic
pattern showed two bands (130 and 76 bp) for homozygous
wild-type C allele, one band (206 bp) for homozygous
mutant T allele and three bands (206, 130 and 76 bp) for
heterozygous CT genotype.
Sequencing analysis
Genotyping of ABCB11236C>T and ABCB12677G>T/A was
performed by automated sequencing. Sequencing-PCR
reaction was performed according to “SequiTherm EX-
CEL™ II DNA Sequencing Kit-LC” protocol (Epicentre
Technologies, Madison, WI, USA).
The reaction mixture for sequencing-PCR amplifica-
tion consisted of amplified DNA, 0.2 μMo fp r i m e r ,
3.5X Sequencing Buffer, 5 U of SequiTherm EXCEL™
II DNA Polymerase, 0.2 mM each dNTP/dideoxyribo-
nucleotide triphosphate and distilled water to a final
volume of 11 μl. Sequencing primers were labelled by
IRD 700 or IRD 800 on 5′ end. Stop/Loading Buffer
was used after sequencing-PCR amplification. The
primer sequences for automated sequencing genotyping
procedure of ABCB11236C>T and ABCB12677G>T/A were
planned by using software Primer3: WWW primer tool
(http://biotools.umassmed.edu/bioapps/primer3_www.
cgi) and GenBank database (http://www.ncbi.nlm.nih.
gov/Genbank/index.html). SeqPCR products after dena-
turation were separated in polyacrylamide gels. Sequenc-
ing was performed with the use of automated sequencer
LI-COR® 4000.
Table 1 Detailed information on the colorectal cancer group
N Median
age
±SD
a
Depth of tumour
invasion
T1 3 54 15.1
T2 26 67 9.1
T3 56 59.5 11.5
T4 10 61 10.5
Lymph node
involvement
N0 59 63 11.7
N1 16 61 10.4
N2 20 63 10.4
Distant metastases M0 76 63 10.8
M1 19 63 12.5
pTNM I 26 67 9.9
II 26 56.5 12.0
III 24 62 8.8
IV 19 63 12.5
Grade of
malignancy
G1 10 56 14.2
G2 57 65 9.6
G3 28 57.5 11.9
Tumour
localization
Rectum 36 64 10.2
Different location 59 66 13.0
Lymphoid
infiltration
(+) 43 63.5 10.6
(−) 52 59 11.5
Vessel invasion Not involved 36 67 9.1
Involved 59 58 11.7
Histological type adenocarcinoma 64 59.5 11.4
mucinous
adenocarcinoma
and medullary
adenocarcinoma
31 65 10.4
Radiotherapy (+) 15 59 9.9
(−) 68 63.5 11.2
Data missing 12 61 11.9
Adjuvant
chemotherapy
(5-FU/LV)
(+) 40 57.5 9.0
(−) 43 69 11.2
Data missing 12 61 11.9
Family
predispositions
(+) 11 64.5 8.5
(−) 21 54 11.7
Data missing 64 63 11.2
Resection status of all patients estimated as R0
(5-FU/LV) 5-fluorouracil and leucovorin
aStandard Deviation
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Statistical significance of the observed genotype frequen-
cies compared to genotype frequencies expected according
to the Hardy–Weinberg rule was evaluated. Data were
analysed using STATISTICA version 8.0 (data analysis
software system, StatSoft Inc.). The differences in allele or
genotype frequencies according to TNM classification,
grade of malignancy, localization of primary carcinoma,
lymphoid infiltration, vessel invasion, gender and family
predispositions to tumours were calculated using Pearson's
chi-square test or Yates' chi-square test. Survival probability
of CRC patients according to genotypes and histological
types were estimated on the basis of the Kaplan–Meier
method and compared between groups using the F Cox test.
The multivariate analysis was performed according to the
Cox's proportional hazards model. The odds ratio (OR),
hazard ratio (HR) and 95% confidence intervals (CI) were
calculated on the basis of logistic regression and the Wald
test. Haplotypes were statistically inferred using PHASE v.
2.1 software. PHASE implements a Bayesian statistical
method for reconstructing haplotypes from population
genotype data [34]. For all analyses, p-values at the level
of 0.05 were considered statistically significant.
Results
The observed genotype frequency distribution did not show
any significant deviation from Hardy–Weinberg equilibri-
um (data not shown).
To assess the clinical utility of ABCB1/MDR1 genotyp-
ing, the results were compared with several clinicopatho-
logical parameters such as depth of tumour invasion (T),
lymph node metastases (N) distant metastases (M) and
clinical staging (pTNM).
The vast majority of cases investigated in this study
(69.5%) belonged to the group with deep-wall penetration
(T3/T4). Only 30.5% belonged to the T1 and T2 groups.
Higher frequency of T1236 allele (genotype CT1236 or TT1236
vs. CC1236) was observed in the less advanced T1/T2 groups
than in the T3/T4 groups (89.7% and 68.2%, respectively;
p=0.0498, OR=4.04 (95% CI=1.14–14.32), measure of
correlation: Fi–Yule coefficient=0.228). There were no
statistically significant differences in haplotype distribution
between the T1/T2 and T3/T4 groups. Statistical dependen-
cies are presented in Table 2.
Genotyping of ABCB1/MDR1 gene in cases with and
without lymph node metastases was also evaluated. In
patients without lymph node metastases (N0 group) the
ABCB13435C>T wild-type genotype (CC3435) was observed in
18.6% of patients, whereas 52.6% were heterozygous
(CT3435) and 28.8% were homozygous for the mutation
(TT3435). In patients with lymph node metastases (N1/N2
groups) the frequencies of ABCB13435C>T genotypes were
different: 33.3% (CC3435), 58.4% (CT3435) and 8.3%
(TT3435)( p=0.037). Moreover, a higher frequency of C3435
allele (genotype CC3435 or CT3435 vs. TT3435) was found in
the N1/N2 groups than the N0 group (91.7% and 71.2%,
respectively; p=0.0344, OR=4.45 (95% CI=0.82–24.29),
measure of correlation: Fi–Yule coefficient=0.244). In
addition, significant differences in C3435 allele distribution
were found (62.5% and 44.9%, respectively; p=0.0186,
OR=2.04 (95% CI=1.07–3.90), measure of correlation:
Fi–Yule coefficient=0.171). There were no statistically
significant differences in haplotype distribution between N0
and N1/N2 groups. Statistical dependencies are summarised
in Table 2.
Genotypes of ABCB1/MDR1 gene were also analysed
in cases with and without distant metastases. Significant
differences in ABCB11236 genotypes distribution were
found (p=0.0057). CC1236 was detected in 18.4% of
subjects without distant metastases (M0 group) and in
52.6% of subjects with distant metastases (M1 group)
(OR=0.20 (95% CI=0.07–0.58)). The frequencies of
CT1236 and TT1236 were higher in the M0 group (71.1%
and 10.5%, respectively) in comparison with the M1
group (47.4% and 0.00%, respectively) (OR=2.73 (95%
CI=0.96–7.78)). Moreover, a higher frequency of T1236
allele (genotype TT1236 or CT1236 vs. CC1236) was found
in the M0 than the M1 group (81.6% and 18.4%,
respectively; p=0.0021, OR=0.20 (95% CI=0.07–0.58),
measure of correlation: Fi–Yule coefficient=0.315). In
addition, significant differences in T1236 allele distribution
were found (46.1% and 23.7%, respectively; p=0.0123,
OR=0.36 (95% CI=0.20–0.67), measure of correlation:
Fi–Yule coefficient=0.182).
Haplotype analysis showed that each of the eight
possible haplotypes was noted in M0 group and only
s e v e ni nM 1g r o u p .H a p l o t y p eT 1236-G2677-C3435 pre-
sented only in the M0 group (frequency 9.2%). However,
the frequencies of C1236-G2677-C3435 and T1236-T2677-
T3435 haplotypes were higher in the M0 group in
comparison with the M1 group (36.2% vs. 15.8%, OR=
3.02 (95% CI=0.93–9.83) and 22.4% vs. 5.3%, OR=5.17
(95% CI=0.70–38.20, respectively)). In addition, the
frequencies of C1236-G2677-T3435 and C1236-T2677-C3435
haplotypes were higher in M1 group in comparison with
M0 group (36.8% vs. 6.6%, OR=0.12 (95% CI=0.05–
0.32) and 18.4% vs 0.7%, OR=0.03 (95% CI=0.00–0.27),
respectively). Furthermore, three of four possible
haplotypes (T1236-T2677-T3435,T 1236-G2677-T3435 and
T1236-G2677-C3435) containing the T1236 allele were more
often registered in the M0 group than in the M1 group
(total frequency of three haplotypes is 0.382 vs. 0.079). In
the case of haplotypes with the C1236 allele, two of them
1170 Int J Colorectal Dis (2010) 25:1167–1176(C1236-T2677-C3435 and C1236-G2677-T3435) were observed
much more frequently in the M1 than the M0 group (total
frequency of three haplotypes is 0.552 vs. 0.073). There
were significant differences in haplotype distributions
between M0 and M1 group (p=0.01). Statistical depen-
dencies are presented in Table 2.
The genotyping results of ABCB1/MDR1 gene we
obtained were compared with clinical staging of neoplasms.
Of the cases investigated in this study, 54.7% belonged to the
group with less clinically advanced neoplasms (I/II degree),
whereas, 45.3% belonged in the III/IV degree group
according to TNM clinical staging classification. A higher
frequency of T1236 allele (genotype TT1236 or CT1236 vs.
CC1236) was detected in I/II than III/IV group (82.7% and
65.1%, respectively; p=0.0497, OR=0.39 (95% CI=0.14–
1.08), measure of correlation: Fi–Yule coefficient=0.201).
Each of the eight possible haplotypes was noted in I/II group
and only seven in III/IV group. Haplotype T1236-G2677-C3435
was presented only in I/II group (frequency 9.6%). In I and II
stage three haplotypes with the T1236 alelle (T1236-T2677-
T3435,T 1236-G2677-T3435 and T1236-T2677-C3435)w e r e
observed more frequently than in III and IV stage (0.423
vs. 0.233). Haplotypes with the C1236 allele (C1236-T2677-
C3435,C 1236-G2677-T3435 and C1236-G2677-C3435)w e r e
observed more often in more advanced stages (0.593 vs.
0.404). There were significant differences in haplotype
distributions between investigated groups (p=0.05). Statisti-
cal dependencies are presented in Table 2.
There was no statistically significant correlation between
ABCB1/MDR1 genotype/allele/haplotype frequencies and
gender, family predispositions to tumours, grading, locali-
zation of primary carcinoma, lymphoid infiltration, or
vessel invasion (Table 3).
The multivariate analysis with the Cox's proportional
hazards model indicated that some of the clinicopatholog-
ical features (approved prognostic factors and the presence
of the studied alleles of the ABCB1/MDR1 gene) have
independent influence on overall survival time of the
Table 2 ABCB1/MDR1 genotype/allele/haplotype frequencies analysis in investigated populations divided according to the pTNM classification
Genotypes
Alleles
Haplotypes
T1/T2 T3/T4 p N0 N1/N2 p M0 M1 p I/II III/IV p
freq freq freq freq freq freq freq freq
CC1236 0.103 0.318 0.085
a 0.237 0.278 0.701
a 0.184 0.526 0.005
a 0.173 0.349 0.099
a
CT1236 0.794 0.606 0.661 0.667 0.711 0.474 0.712 0.604
TT1236 0.103 0.076 0.102 0.056 0.105 0.000 0.115 0.047
CC1236/CT1236 0.897 0.924 0.963
b 0.898 0.944 0.686
b 0.895 1.000 0.310
b 0.885 0.953 0.405
b
TT1236 0.103 0.076 0.102 0.056 0.105 0.000 0.115 0.047
CT1236/TT1236 0.897 0.682 0.049
b 0.723 0.722 0.660
a 0.816 0.474 0.002
a 0.827 0.651 0.049
a
CC1236 0.103 0.318 0.237 0.278 0.184 0.526 0.173 0.349
C1236 0.500 0.621 0.119
a 0.568 0.611 0.557
a 0.539 0.763 0.012
a 0.529 0.651 0.089
a
T1236 0.500 0.379 0.432 0.389 0.461 0.237 0.471 0.349
CC3435 0.172 0.273 0.431
a 0.186 0.333 0.037
a 0.237 0.263 0.969
a 0.192 0.302 0.215
a
CT3435 0.552 0.545 0.526 0.584 0.553 0.526 0.538 0.558
TT3435 0.276 0.182 0.288 0.083 0.210 0.211 0.270 0.140
CC3435/CT3435 0.724 0.818 0.301
a 0.712 0.917 0.034
b 0.790 0.789 0.753
b 0.730 0.860 0.123
a
TT3435 0.276 0.182 0.288 0.083 0.210 0.211 0.270 0.140
CT3435/TT3435 0.828 0.727 0.429
b 0.814 0.667 0.105
a 0.763 0.737 0.952
b 0.808 0.698 0.213
a
CC3435 0.172 0.273 0.186 0.333 0.237 0.263 0.192 0.302
C3435 0.448 0.545 0.217
a 0.449 0.625 0.018
a 0.513 0.526 0.885
a 0.462 0.581 0.099
a*
T3435 0.552 0.455 0.551 0.375 0.487 0.474 0.538 0.419
C1236-T2677-T3435 0.086 0.076 0.22
c 0.085 0.083 0.13
c 0.105 0.053 0.01
c 0.125 0.058 0.05
c
C1236-T2677-C3435 0.000 0.083 0.051 0.097 0.007 0.184 0.010 0.081
C1236-G2677-T3435 0.069 0.152 0.178 0.097 0.066 0.368 0.077 0.163
C1236-G2677-C3435 0.345 0.311 0.254 0.333 0.362 0.158 0.317 0.349
T1236-T2677-T3435 0.293 0.212 0.254 0.194 0.224 0.053 0.240 0.198
T1236-T2677-C3435 0.052 0.045 0.051 0.014 0.079 0.158 0.087 0.035
T1236-G2677-T3435 0.103 0.015 0.034 0.000 0.092 0.000 0.096 0.000
T1236-G2677-C3435 0.052 0.106 0.093 0.181 0.066 0.026 0.048 0.116
aPearson's chi-square test
bYates' chi-square test
cPermutation test
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hazard model)
Number of deaths in % HR
a CI (95%)
b Wald
statistic
p-
value
Gender
Women 39.6 1.00 (−1.87)–(+4.96) 0.7912 0.3737
Men 36.2 1.55
Family predispositions
Negative 38.1 1.00 (−1.99)–(+3.99) 0.4341 0.5060
Positive 18.2 1.00
Tumour localization
Different location 33.9 1.00 (−1.08)–(+4.77) 1.5381 0.2149
Rectum 44.4 1.84
Depth of tumour invasion
T1 or T2 27.6 1.00 (+1.89)–( +7.63) 10.5496 0.0012
T3 or T4 42.4 4.76
Lymph node involvement
N0 28.8 1.00 (−4.17)–(+7.50) 0.3122 0.5763
N1 or N2 52.8 1.66
Distant metastases
M0 26.3 1.00 (+6.87)–(+23.93) 12.5597 0.0004
M1 84.2 15.40
pTNM classification
I or II 25.0 1.00 (−0.04)–(+0.31) 2.3573 0.1247
III or IV 52.5 0.14
Grade of malignancy
G1 or G2 38.8 1.00 (−0.78)–(+2.22) 0.8893 0.3457
G3 35.7 0.72
Histological type
adenocarcinoma 34.4 1.00 (+0.52)–(+3.15) 7.5484 0.0060
mucinous adenocarcinoma and medullary adenocarcinoma 45.2 1.83
Vessel invasion
Not involved 30.6 1.00 (−2.65)–(+4.22) 0.2009 0.6540
Involved 42.4 0.79
Lymphoid infiltration
(−) 44.2 1.00 (−2.83)–(+4.39) 0.1786 0.6726
(+) 30.2 0.78
Allele C1236
TT1236 10.5 1.00 (−4.10)–(+5.62) 0.0936 0.7597
CC1236 or CT1236 44.7 0.76
Allele T1236
CC1236 22.0 1.00 (0.01)–(+0.52) 4.1204 0.0424
CT1236 or TT1236 50.0 0.26
Allele G2677
TT2677 38.1 1.00 (−1.13)–(+5.44) 1.6514 0.1988
GG2677 or GT2677 35.1 2.15
Allele T2677
GG2677 37.1 1.00 (−1.15)–(+5.25) 1.5757 0.2093
GT2677 or TT2677 36.7 2.05
Allele C3435
TT3435 45.0 1.00 (−0.83)–(+2.07) 0.7072 0.4004
CC3435 or CT3435 36.0 0.62
Allele T3435
CC3435 32.0 1.00 (−18.40)–(+20.30) 0.0093 0.9232
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2=40.4963; df=19;
p=0.0028).
As prognostic factors, the following maintained their
independence: depth of tumour invasion (HR=4.76;
p=0.0012), distant metastases (HR=15.40; p=0.0004),
histological type of tumour (HR=1.83; p=0.0060) and the
presence of the T1236 allele (HR=0.26; p=0.0424). Further-
more, it was demonstrated that, with regard to the objective,
the T1236 allele is the important one and seems to be a good
independent prognostic factor because patients possessing it
(TT1236 or CT1236 genotype) can be characterised by lower
risk of death in comparison to patients without this allele
(CC1236 gentotype) (HR < 1). The results of our multivariate
analysis of cancer factors influence on overall survival of the
95 patients with CRC disease are presented in Table 3.
Kaplan–Meyer curves presenting survival probability with
time depending on T1236 allele (CC1236 vs. TT1236 or CT1236
genotype) and histological type (adenocarcinoma vs. mucin-
ous adenocarcinoma and medullary adenocarcinoma) based
on statistical analysis with the use of F Cox test are presented
in Figs. 1 and 2.
Discussion
Relations between the presence of different SNPs and the
risk of CRC development is being investigated in over 35
different genes [35]. Among them, ABCB1/MDR1 is
studied extensively.
Gaikovitch indicated a higher risk (1.65-fold) of
colorectal cancer development among CC3435 genotype
carriers than among T3435 allele carriers. Similarly, the
presence of T2677 allele decreases the risk of colorectal
cancer development in relation to G2677 allele [36]. A
protective role of T3435 and T2677 alleles (possibly also
T1236 allele) may be associated with the function of P-gp
protein, which influences functions of c-Myc and cyclin
D1 and contributes to unblocking cell death pathways
suppression. Robinson indicated that apoptosis of cells
transfected with the ABCB1/MDR1 gene is reversible
through P-gp verapamil inhibition [37]. Other studies also
indicate the antiapoptotic function of P-gp visible in its
cell protection against cytotoxic compounds activating a
caspase pathway and also against pro-apoptotic influence
of TNF [38]. It was indicated that P-gp can protect cells
against apoptosis by its influence on the sphingomyelin–
ceramide pathway [39, 40].
In this study, three polymorphisms were analysed, one
leading to amino acid exchange (ABCB12677G>T/A) and two
silent ones, which have no influence on the amino acid
sequence of P-gp but, surprisingly, may influence P-gp
Table 3 (continued)
Number of deaths in % HR
a CI (95%)
b Wald
statistic
p-
value
CT3435 or TT3435 40.0 0.95
Adjuvant combined chemotherapy (5-FU/LV)
No 39.5 1.00 (−3.02)–(+5.67) 0.3570 0.5502
Yes 45.0 1.32
Radiotherapy
No 42.6 1.00 (−1.57)–(+3.06) 0.3977 0.5283
Yes 40.0 0.74
Cox's proportional hazard model: chi-square test (χ
2)=40.4963; degrees of freedom (df)=19; p-value=0.0028
(5-FU/LV) 5-fluorouracil and leucovorin
ahazard ratio
b95% confidence interval for hazard ratio
Fig. 1 Adjusted survival probability of colorectal cancer patients
according to T1236 allele (CC1236 vs. TT1236 or CT1236 genotype) F
Cox test: T1=33.16845, T2=9.831555, F(60.24)=1.349469, p=0.05
Int J Colorectal Dis (2010) 25:1167–1176 1173function(ABCB11236C>T and ABCB13435C>T). There are
several hypotheses regarding the influence of a silent
polymorphism on phenotypically revealed features and
predispositions. One hypothesis assumes the possibility of
influence of a synonymous triplet on the efficiency of
translation [41]. Other authors suggest that the allele-
specific differences in the RNA secondary structure may
influence the splicing process or the translation process
control [42]. It is also possible that some of SNPs increase
the mRNA stability and in consequence leads to increased
protein expression [43] and/or a change of the substrate's
affinity to the P-gp transporter [44]. The changed function
of P-gp could be a risk and progression factor of CRC due
to it facilitating intracellular penetration of DNA damaging
factor of both exo- and endogenous origin.
The impact of ABCB11236C>T and ABCB13435C>T poly-
morphisms on the function ofP-gp can also be explained by
the importance of LD. In our previous study it was proven
that three investigated SNPs of the ABCB1/MDR1 gene
(ABCB11236C>T, ABCB12677G>T/A and ABCB13435C>T) are
located in one haploblock [32] .T h ep r e s e n c eo ft h e
mentioned haplotype structure within the ABCB1/MDR1
gene was also described by other authors [22]. The
haplotype may often provide more useful information than
the genotype about interindividual and interethnic differ-
ences [45]. Kroetz defined 32 haplotypes and their subtypes
in ABCB1/MDR1 gene (64 distinct haplotypes obtained for
28 variant sites) [20]. In our study, haplotype T1236-G2677-
C3435 was presented only in M0 or I/II groups. Further-
more, three of four possible haplotypes (T1236-T2677-T3435,
T1236-G2677-T3435 and T1236-G2677-C3435) containing the
T1236 allele were more often registered in the M0 than in
the M1 group. In instances of haplotypes with the C1236
allele, two of them (C1236-T2677-C3435 and C1236-G2677-
T3435) were observed much more frequently in the M1 than
M0 group. A similar trend was observed when comparing
groups regarding haplotype frequency in relation to clinical
stage of the disease. In stages I and II, three haplotypes with
the T1236 allele (T1236-T2677-T3435,T 1236-G2677-T3435 and
T1236-T2677-C3435) were observed more frequently than in
stages III and IV. Haplotypes with the C1236 allele (C1236-
T2677-C3435,C 1236-G2677-T3435 and C1236-G2677-C3435) were
observed more often in more advanced stages. There were
significant differences in haplotype distributions between
groups I/II and III/IV. Since the presence of the T1236 allele
is related to lower disease development risk and lower
disease advancement, a protective effect of this allele can
be deducted, especially in the context of the possible
influence of this SNP on P-gp function related to the cell
cycle control. To the best of our knowledge, this is the first
report of frequent polymorphism ABCB11236C>T affecting
the genetic factor for progression of CRC.
ABCB1/MDR1 is highly expressed in lymphocytes,
including CD8+, CD4+ T cells, and DC, and it is able to
transport several cytokines and chemokines. Lymphocytes
play an important role in the response of the immunological
system to the presence of tumour cells through releasing
cytokines with possible P-gp mediation (secretion of IL-2,
IL-4 and interferon-γ)[ 46]. In this paper, a higher
frequency of C3435 allele in N1/N2 groups in comparison
to N0 group is reported. Moreover, differences in C3435
allele distribution and genotypes distribution between cases
with and without lymph node metastases were noticed.
This study shows that patients possessing the T1236 allele
(TT1236 or CT1236 genotype) have a higher survival chance
in comparison to patients without this allele. The results
confirm the previously described possible protective function
of this allele. However, there is no data regarding the
possible direct influence of the ABCB11236C>T polymorphism
on P-gp function, especially on this protein expression level.
Kimchi-Sarfaty indicated that there is dependency between
the ABCB13435C>T silent polymorphism and posttranslational
protein folding and its acquiring proper transport activities
[44]. It is also necessary to determine the influence of the
P-gp protein activity on CRC progression. The level of P-gp
expression is known to correlate with worse prognosis in the
course of leukaemia (AML) [47, 48]. Some researches
indicate that P-gp expression level influences disease-free
survival [30], however, no relationship was seen between
P-gp expression, genotypes of ABCB12677G>T/A and
ABCB13435C>T and long-term prognosis of CRC [25].
Fig. 2 Adjusted survival probability of colorectal cancer patients
according to histological type (adenocarcinoma vs. mucinous adeno-
carcinoma and medullary adenocarcinoma) F Cox test: T1=30.52871,
T2=12.47129, F(50. 34)=1.664585, p=0.05
1174 Int J Colorectal Dis (2010) 25:1167–1176On the basis of this and previously published data, it could
be suggested that other potential SNPs, especially in the
regulatory region of the ABCB1/MDR1 gene, may also
influence P-gp expression and function, e.g. ABCB1-2410T>C,
ABCB1-1910T>C, ABCB1-692T>C and ABCB1-129T>C [27, 47,
49]. Mutations in the promoter region of ABCB1/MDR1
gene were shown to be associated with haematological
malignancies [50]. Potocnik identified the promoter
polymorphism (+8 T>C) and located it in intron 1
(IVS1-81 delG) of the ABCB1/MDR1 gene, which was
related to low expression of P-gp and the presence of the
lymphoid infiltration [29].
In conclusion, correlations between ABCB11236C>T poly-
morphism and haplotypes with allele T1236 and CRC
progression were identified. Differences between haplotype
distributions at different clinical stages of the disease
suggest that other potential SNPs, especially in the
regulatory region of the ABCB1/MDR1 gene, may influence
progression of CRC via functional changes in P-gp. This
research also supports the role of P-gp in the initiation and
progression of CRC development, thus reinforcing the idea
of multiple physiological functions for P-gp.
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